These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 19151750)
21. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650 [TBL] [Abstract][Full Text] [Related]
22. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma. Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410 [TBL] [Abstract][Full Text] [Related]
23. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547 [TBL] [Abstract][Full Text] [Related]
24. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Abaan OD; Levenson A; Khan O; Furth PA; Uren A; Toretsky JA Oncogene; 2005 Apr; 24(16):2715-22. PubMed ID: 15782144 [TBL] [Abstract][Full Text] [Related]
25. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
26. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
27. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
28. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264 [TBL] [Abstract][Full Text] [Related]
29. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma. Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673 [TBL] [Abstract][Full Text] [Related]
31. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530 [TBL] [Abstract][Full Text] [Related]
32. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607 [TBL] [Abstract][Full Text] [Related]
33. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Ladanyi M Cancer Biol Ther; 2002; 1(4):330-6. PubMed ID: 12432241 [TBL] [Abstract][Full Text] [Related]
34. Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms. France KA; Anderson JL; Park A; Denny CT J Biol Chem; 2011 Jul; 286(26):22750-7. PubMed ID: 21531709 [TBL] [Abstract][Full Text] [Related]
35. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056 [TBL] [Abstract][Full Text] [Related]
36. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820 [TBL] [Abstract][Full Text] [Related]
37. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
38. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors. Anderson JL; Titz B; Akiyama R; Komisopoulou E; Park A; Tap WD; Graeber TG; Denny CT Mol Cancer Res; 2014 Dec; 12(12):1740-54. PubMed ID: 25092916 [TBL] [Abstract][Full Text] [Related]
39. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673 [TBL] [Abstract][Full Text] [Related]